AR058749A1 - Inhibidores de c3-convertasa para la prevencion y el tratamiento de la degeneracion macular relacionada con la edad en pacientes con variantes de riesgo de factor h de complemento - Google Patents

Inhibidores de c3-convertasa para la prevencion y el tratamiento de la degeneracion macular relacionada con la edad en pacientes con variantes de riesgo de factor h de complemento

Info

Publication number
AR058749A1
AR058749A1 ARP060105794A ARP060105794A AR058749A1 AR 058749 A1 AR058749 A1 AR 058749A1 AR P060105794 A ARP060105794 A AR P060105794A AR P060105794 A ARP060105794 A AR P060105794A AR 058749 A1 AR058749 A1 AR 058749A1
Authority
AR
Argentina
Prior art keywords
risk
polymorphism
amd
patient
age
Prior art date
Application number
ARP060105794A
Other languages
English (en)
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of AR058749A1 publication Critical patent/AR058749A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Métodos para identificar a un paciente en riesgo de desarrollar DMRE mediante la identificacion de la presencia del polimorfismo Y402H o de otras variantes de riesgo en el gen el factor H de complemento. Además métodos para el tratamiento de personas que tienen DMRE o que se encuentran en riesgo de desarrollar DMRE como resultado e poseer el polimorfismo Y402H u otras variantes de riesgo en el gen del factor H de complemento. Reivindicacion 1: Un método para inhibir la pérdida de la agudeza visual asociada con la degeneracion macular relacionada con la edad (DMRE) en un paciente que posee DMRE o que se encuentra en riesgo de desarrollar DMRE debido a la presencia de un polimorfismo Y402H o de otra variante de riesgo, comprendiendo dicho método: a) identificar dicho polimorfismo Y402H u otra variante de riesgo en dicho paciente mediante i) la obtencion de una muestra de tejido de dicho paciente; y ii) el ensayo de dicha muestra de tejido en cuanto a la presencia del polimorfismo Y402H o de otra variante de riesgo, en donde la presencia del polimorfismo Y402H o de otra variante de riesgo indica un incremento en el riesgo de desarrollo de DMRE o en la progresion de la DMRE seca a la DMRE humeda; b) administrar a un paciente a quien se identifico en la etapa (a) precedente como poseyendo el polimorfismo Y402H u otra variante de riesgo una cantidad terapéuticamente efectiva de una composicion que comprende un inhibidor de C3-convertasa.
ARP060105794A 2005-12-22 2006-12-26 Inhibidores de c3-convertasa para la prevencion y el tratamiento de la degeneracion macular relacionada con la edad en pacientes con variantes de riesgo de factor h de complemento AR058749A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75313505P 2005-12-22 2005-12-22

Publications (1)

Publication Number Publication Date
AR058749A1 true AR058749A1 (es) 2008-02-20

Family

ID=38218828

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105794A AR058749A1 (es) 2005-12-22 2006-12-26 Inhibidores de c3-convertasa para la prevencion y el tratamiento de la degeneracion macular relacionada con la edad en pacientes con variantes de riesgo de factor h de complemento

Country Status (12)

Country Link
US (1) US20070149616A1 (es)
EP (1) EP1963529A2 (es)
JP (1) JP2009521506A (es)
KR (1) KR20080087814A (es)
CN (1) CN101346473A (es)
AR (1) AR058749A1 (es)
AU (1) AU2006330501B2 (es)
BR (1) BRPI0620249A2 (es)
CA (1) CA2631958A1 (es)
TW (1) TW200731984A (es)
WO (1) WO2007076437A2 (es)
ZA (1) ZA200805148B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US20110092446A1 (en) * 2007-07-20 2011-04-21 Cedric Francois Compositions and methods for treatment of trauma
KR20150080007A (ko) * 2007-10-02 2015-07-08 포텐시아 팔마큐티칼스, 인크. 겔로부터 콤스타틴 유사체의 지속적 운반
WO2009059317A2 (en) 2007-11-01 2009-05-07 University Of Iowa Research Foundation Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715
WO2009121065A2 (en) * 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
EP3660033B9 (en) 2012-11-15 2022-06-22 Apellis Pharmaceuticals, Inc. Long-acting compstatin analogs and related compositions and methods
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
KR102314785B1 (ko) * 2015-04-21 2021-10-19 인제대학교 산학협력단 신규한 황반변성 진단용 마커 및 황반변성 진단방법
EP3359555B1 (en) 2015-10-07 2023-12-20 Apellis Pharmaceuticals, Inc. Dosing regimens
AU2017210042B2 (en) 2016-01-20 2021-01-21 396419 B.C. Ltd. Compositions and methods for inhibiting Factor D
WO2017148904A1 (en) * 2016-02-29 2017-09-08 Franz Grus Predictive markers useful in the treatment of wet age-related macular degeneration
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
CA3059304A1 (en) 2017-04-07 2018-10-11 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043268A (en) * 1990-05-04 1991-08-27 The Trustees Of Princeton University Substrates and inhibitors for prenyl cysteine methyltransferase enzymes
US6413245B1 (en) * 1999-10-21 2002-07-02 Alcon Universal Ltd. Sub-tenon drug delivery
DE60136272D1 (de) * 2000-04-29 2008-12-04 Univ Iowa Res Found Diagnostika und therapeutika für makula degeneration erkrankungen
CA2516790A1 (en) * 2003-02-20 2004-09-02 Alcon, Inc. Formulations of glucocorticoids to treat pathologic ocular angiogenesis
CN103920142A (zh) * 2005-02-14 2014-07-16 爱荷华大学研究基金会 治疗和诊断年龄相关性黄斑变性的方法和试剂
PL1951279T3 (pl) * 2005-10-08 2017-12-29 Apellis Pharmaceuticals, Inc. Kompstatyna i jej analogi w zaburzeniach oczu

Also Published As

Publication number Publication date
AU2006330501A1 (en) 2007-07-05
ZA200805148B (en) 2009-12-30
TW200731984A (en) 2007-09-01
BRPI0620249A2 (pt) 2011-11-08
CA2631958A1 (en) 2007-07-05
WO2007076437A2 (en) 2007-07-05
WO2007076437A3 (en) 2008-01-31
JP2009521506A (ja) 2009-06-04
AU2006330501B2 (en) 2012-04-05
EP1963529A2 (en) 2008-09-03
US20070149616A1 (en) 2007-06-28
KR20080087814A (ko) 2008-10-01
CN101346473A (zh) 2009-01-14

Similar Documents

Publication Publication Date Title
AR058749A1 (es) Inhibidores de c3-convertasa para la prevencion y el tratamiento de la degeneracion macular relacionada con la edad en pacientes con variantes de riesgo de factor h de complemento
AR066292A1 (es) Tratamiento para la degeneracion macular relacionada con el envejecimiento utilizando inhibidores de factor d complementario
AR116859A2 (es) Métodos para tratar la esclerosis múltiple progresiva
WO2009012468A3 (en) Differential expression of micrornas in nonfailing versus failing human hearts
CY1122973T1 (el) Συνθεση υγρου διαπιδυσης η οποια περιλαμβανει ουσιες αναστολης της κρυσταλλωσης
MX2012001716A (es) Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf.
AR057631A1 (es) Composiciones y metodos para incrementar la sensibilidad a insulina
BRPI0518289A2 (pt) mÉtodos e composiÇÕes para o tratamento de desordens oculares
WO2008042231A3 (en) Compositions and methods for evaluating and treating heart failure
ATE446102T1 (de) Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii
CO6390109A2 (es) Inhibidores de syk de imidazopirazina
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
BRPI0412909A (pt) uso de rnai inibindo atividade de parp para a fabricação de um medicamento para o tratamento de cáncer
ATE456955T1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
CL2017002825A1 (es) Formulaciones de tpp1 y métodos para tratar la enfermedad de cln2
DE602006011607D1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
WO2006047475A3 (en) Detection and analysis of ophthalmically-relevant fluorescent molecules
MX2016016139A (es) Inhibidor del sistema complemento de ornithodoros moubata para utilizarse en el tratamiento de enfermedades mediadas por el sistema complemento en pacientes con polimorfismo de c5.
HK1110207A1 (en) Ophthalmic compositions and methods of using the same
Hatta et al. Nicotine reduced MMP‐9 expression in the primary porcine tenocytes exposed to cyclic stretch
ES2521674T3 (es) Métodos de tratamiento de hiperuricemia y estados patológicos asociados
WO2009027703A3 (en) Identifying organ damage
Freese et al. Environmental enrichment reduces cocaine neurotoxicity during cocaine-conditioned place preference in male rats
EP2716285A3 (en) New method for identifying compounds useful for treating and/or preventing diseases associated with bone loss
MX2020007619A (es) Intervenciones dirigidas, encaminadas a reducir los niveles de succinato circulante en un sujeto, y kits y metodo para determinar la eficacia de dichas intervenciones.

Legal Events

Date Code Title Description
FB Suspension of granting procedure